ThromboGenics NV changed the name and becomes Oxurion NV in September 2018. Oxurion NV (Euronext Brussels: OXUR), is a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye diseases.

Oxurion has a highly competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edema (DME), two key areas of unmet medical need. The Oxurion pipeline consists of products with different modes of action, and includes: (1) THR-317, a human placental growth factor (PlGF) neutralizing monoclonal antibody, is in a Phase 2 study evaluating the efficacy and safety of intravitreal THR-317 when administered in combination with ranibizumab (Lucentis®), for the treatment of DME. Results from this Phase II study are expected for the end of 2019. (2) THR-149 is a potent plasma kallikrein inhibitor being developed for the treatment of DME. It is in a Phase 1 open-label, multicenter, dose escalation study. Result from this study are anticipated towards the end of 2019. (3) THR-687, a small molecule pan RGD integrin antagonist, is being developed to treat a broad range of patients with diabetic eye disease. THR-687 entered the clinic in September 2018. Results from this Phase I study are expected towards the end of 2019.

OXU will participate in WP1, WP2, WP8, and WP9.